Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study |
| April 28, 2021 | April 2021 Bond Updates |
|
THOUSAND OAKS, Calif., April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized clinical trial to compare the safety and... |
| View more at: https://www.prnewswire.com:443/news-releases/amgen-provides-updated-information-on-lumakras-sotorasib-dose-comparison-study-301278732.html |